Form 4: CYTK Director Henderson Acquires Shares
Insider Transaction Report
Cytokinetics Director John T. Henderson acquired 334 shares of common stock at $63.44 per share as equity compensation.
Summary
- Director John T. Henderson acquired 334 shares of Cytokinetics Inc. common stock.
- The transaction occurred on January 15, 2026, with shares priced at $63.44 each.
- These shares were fully vested and received in lieu of a cash retainer, part of an Equity in Lieu of Cash Retainer Option for Board members.
- Following this transaction, Mr. Henderson directly owns 74,912 shares and indirectly owns 83 shares through his spouse.
Sentiment
Score: 5
Explanation: The filing reports a routine insider transaction (equity compensation for a director), which is generally neutral in sentiment. It indicates standard corporate governance and director remuneration practices without significant positive or negative implications for the company's operational or financial performance.
Positives
- Director John T. Henderson increased his direct ownership in Cytokinetics Inc. by 334 shares, aligning his interests further with shareholders.
- The acquisition was part of an equity compensation plan, indicating a standard practice for director remuneration.
Future Outlook
This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.
Industry Context
This routine insider transaction reflects a common practice in the biotechnology and pharmaceutical industry where directors receive equity compensation, aligning their interests with long-term company performance. It does not indicate any specific broader industry trends or competitive shifts.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Director Compensation | Director John T. Henderson received fully vested shares of common stock in lieu of a cash retainer, pursuant to an Equity in Lieu of Cash Retainer Option available to Board members. | 01/15/2026 | This reflects a standard practice of aligning director incentives with shareholder interests through equity compensation, reinforcing corporate governance principles. |
Related Party Transactions
- Director John T. Henderson received 334 shares of common stock from Cytokinetics Inc. as compensation, which is a related party transaction between the company and a member of its Board of Directors.
Stakeholder Impact
- Shareholders: Increased alignment of a director's interests with shareholders due to increased equity ownership.
- Employees/Customers/Suppliers/Creditors: No direct impact from this routine insider transaction.
Key Dates
| Date | Description |
|---|---|
| 01/15/2026 | Date of transaction where John T. Henderson acquired common stock. |
| 01/16/2026 | Date the Form 4 was signed by the attorney-in-fact for Dr. Henderson. |
Keywords
Cytokinetics, CYTK, Form 4, Insider Trading, Director Stock Acquisition, Equity Compensation, John T. Henderson, Common Stock
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.